ProQR Therapeutics N.V. | Mutual Funds
Mutual Funds that own ProQR Therapeutics N.V.
Prudential Jennison Health Sciences Fund
1,725,935
5.41%
0
0.52%
07/31/2018
Hoofbosch Beleggingsfonds
300,000
0.94%
300,000
1.15%
12/31/2016
ClearBridge Aggressive Growth Fund
288,683
0.9%
-1,322
0.02%
12/31/2017
CI Global Health Sciences Corporate Class
191,360
0.6%
-19,196
0.77%
06/30/2017
Franklin Biotechnology Discovery Fund
123,300
0.39%
0
0.07%
03/31/2018
Legg Mason Global Funds Plc - ClearBridge US Agressive Growth
100,000
0.31%
0
0.04%
07/31/2018
Met Investors - ClearBridge Aggressive Growth Portfolio
88,300
0.28%
0
0.02%
03/31/2018
66,812
0.21%
32,423
0.03%
12/31/2017
Franklin K2 Alternative Strategies Fund
39,735
0.12%
0
0.02%
03/31/2018
Fidelity Advisor Biotechnology Fund
19,545
0.06%
-218,371
0.01%
07/31/2018
| Address |
Zernikedreef 9
Leiden Zuid-Holland 2333 CK
Netherlands
|
|
Employees
|
- |
| Website |
http://www.proqr.com |
| Updated |
07/08/2019 |
| ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands. |
